Valuation: NovoCure Limited

Market Cap 1.7B 1.53B 1.41B 1.28B 2.39B 162B 2.42B 16.91B 6.72B 84.76B 6.39B 6.25B 269B P/E 2026 *
-11.8x
P/E 2027 * -17.9x
Enterprise Value 1.6B 1.43B 1.32B 1.2B 2.24B 152B 2.27B 15.87B 6.3B 79.51B 5.99B 5.87B 252B EV / Sales 2026 *
2.2x
EV / Sales 2027 * 1.85x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day-1.27%
1 week-7.50%
Current month-9.59%
1 month-8.91%
3 months-11.59%
6 months+18.98%
Current year+11.52%
1 week 14.11
Extreme 14.11
15.66
1 month 13.76
Extreme 13.76
16.44
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
120.03
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Director/Board Member 68 31/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 A Free

Chief Executive Officer

1,905 0.0016%
6/30/26 A Free

Head of Human Resources

1,905 0.0016%
6/30/26 A Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%-7.50%+7.85%+10.41% 1.7B
+0.05%+1.79%-19.19%+10.01% 178B
+0.44%+0.45%-20.48%+13.85% 116B
+1.36%+0.96%+0.74%+34.23% 115B
-1.87%+2.59%-43.84%+5.95% 93.1B
-0.29%-4.98%-3.63%+74.46% 62.09B
+0.17%-0.34%+10.87%+84.40% 55.87B
+0.78%+0.58%+6.11%-22.15% 53.12B
+0.45%+0.47%-12.34%+40.29% 44.22B
+0.66%+2.79%-3.33%-8.99% 33.59B
Average -0.02%+1.35%-7.72%+24.25% 75.27B
Weighted average by Cap. +0.05%+2.35%-12.92%+23.30%

Financials

2026 *2027 *
Net sales 726M 652M 602M 546M 1.02B 68.97B 1.03B 7.21B 2.87B 36.15B 2.73B 2.67B 115B 805M 722M 667M 605M 1.13B 76.44B 1.14B 8B 3.18B 40.07B 3.02B 2.96B 127B
Net income -142M -127M -118M -107M -199M -13.49B -202M -1.41B -560M -7.07B -533M -522M -22.42B -84.78M -76.09M -70.26M -63.71M -119M -8.05B -121M -842M -335M -4.22B -318M -311M -13.39B
Net Debt -105M -94.67M -87.41M -79.27M -148M -10.02B -150M -1.05B -416M -5.25B -396M -387M -16.65B -210M -188M -174M -158M -295M -19.94B -298M -2.09B -828M -10.45B -788M -771M -33.14B
Projected Income Statement - Annual - NovoCure Limited
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
28/10/26 $14.42 -1.37% 20,850
27/10/26 $14.62 +1.53% 2,465,526
26/10/26 $14.40 -1.91% 1,166,274
23/10/26 $14.68 -2.78% 1,125,130
22/10/26 $15.10 -3.14% 1,059,800
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - NovoCure Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
14.62USD
Average target price
26.86USD
Spread / Average Target
+83.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NovoCure Limited
  1. Stock Market
  2. Stocks
  3. NVCR Stock